Immuneering Corp (IMRX) concluded trading on Wednesday at a closing price of $1.13, with 4.53 million shares of worth about $5.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.03% during that period and on July 31, 2024 the price remained unchanged. Currently the company’s common shares owned by public are about 29.27M shares, out of which, 21.00M shares are available for trading.
Stock saw a price change of -1.74% in past 5 days and over the past one month there was a price change of -3.42%. Year-to-date (YTD), IMRX shares are showing a performance of -84.63% which decreased to -88.88% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.05 but also hit the highest price of $10.99 during that period. The average intraday trading volume for Immuneering Corp shares is 250.38K. The stock is currently trading -4.80% below its 20-day simple moving average (SMA20), while that difference is down -15.77% for SMA50 and it goes to -72.86% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Immuneering Corp (NASDAQ: IMRX) currently have 29.27M outstanding shares and institutions hold larger chunk of about 34.50% of that.
The stock has a current market capitalization of $33.50M and its 3Y-monthly beta is at -0.60. It has posted earnings per share of -$1.86 in the same period. It has Quick Ratio of 14.38 while making debt-to-equity ratio of 0.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IMRX, volatility over the week remained 8.61% while standing at 9.21% over the month.
Stock’s fiscal year EPS is expected to drop by -6.00% while it is estimated to increase by 13.62% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on March 15, 2024 offering a Buy rating for the stock and assigned a target price range of between $20 and $15 to it. On March 15, 2024, Jefferies Downgrade their recommendations, while on December 01, 2023, Needham Initiated their ratings for the stock with a price target of $20. Stock get an Outperform rating from Oppenheimer on June 26, 2023.
